2024-02-13T00:00:00.000+11:00
Ongoing

FURMO-002

FURMO-002
Lung cancer

A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumor activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.

A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumor activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFRor her2 mutations.

Trial overview

Topic

Lung cancer

Trial registration

Number: NCT05364073

Study details

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel 
with or without cetuximab in participants with locally advanced or metastatic squamous 
Non-Small Cell Lung Cancers

Further information

Please click here for more information

Location

GenesisCare North Shore – PI: Dr Nick Pavlakis

GenesisCare North Shore – PI: Dr Nick Pavlakis :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.